Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2019. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) through the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Instrument | Transaction Type | Transaction Date | Price per Share | Total Volume |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition (Dividend Re-investment) | April 11, 2019 | £15.7582 | 558 shares |
Note: The total volume of 558 shares is the aggregate of 12 individual transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It documents routine compliance disclosures for share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and relate to shares held through the Company's Share Reward Plan.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (558 shares) against the company's insider trading registry.
- Confirm the share price of £15.7582 aligns with the market price on April 11, 2019.
- Review the company's Share Reward Plan rules to understand the mechanics of the dividend re-investment.
- Note that this filing contains no operational or financial performance data; refer to the most recent Form 20-F or quarterly earnings release for those metrics.